Bodybuilders and others who want to increase muscle growth use Dindolyl Methane (or DIM). Recent studies have shown that DIM can pose health risks. DIM can cause liver damage if consumed in excess. Another risk is kidney damage, which can lead to kidney failure. Many bodybuilders and athletes are worried about the long-term health risks associated with DIM.
To increase the production of testosterone, most people take a diindolylmethane supplemental. It is well-known that testosterone functions as an androgen. This means that it can cause hormonal changes within the tissues. DIM has been shown in studies to mimic the effects of testosterone, along with other hormones. Because men produce much more testosterone than women do Certain manufacturers have added diindolylmethane into their products in order to make them more competitive in male circles. The theory is that men respond to a product that mimics the effects of natural testosterone.
Many companies promote DIM as a tumor suppressor. Although diindolylmethane can be effective in reducing the growth of tumors in laboratory animals, it was administered orally to the animals. To achieve the same result in humans, diindolylmethane would have to be consumed in large doses over a prolonged period of time. The animals that were studied had no symptoms of cancer for several years. However, they all developed liver disease after consuming excessive amounts of diindolylmethane. A doctor can give you an understanding of the way DIM functions within the body.
The only way to establish that DIM is effective in treating breast cancer is to do an experiment where cells from healthy breast cells are exposed to high doses of diindolylmethane for long periods of time. As with any chemical, there are both pros and cons to using it. The ability to mimic hormones is one of the advantages. This lets you create insulin which can inhibit cancer cell growth. The downsides are that diindolylmethane is also able to produce a potentially harmful chemical called DMSO. Learn more about what is diindolylmethane here.
One of the most popular claims made about diindolylmethane a treatment for different health issues is that it functions as a natural, antibacterial, anti-fungal, and anti-cancer agent. The National Institute of Health, in their exhaustive review of the supporting evidence, concluded that there was no basis for these claims. According to the Institute of Chemical Technology there was no evidence from any research which supported this assertion. The Institute of Chemical Safety, conducting an in-depth study of the safety profile of the firestone concluded that the evidence offered by pharmaceutical companies on the benefits of diindolylmethane for humans were not entirely reliable.
In a May 2021 edition of the Journal of Toxicology and Environmental Health, van der Goes, and others. highlighted the potential risks related to the use of diindolylmethane, including allergic reactions, skin rash, asthma attacks, dizziness, headaches, and respiratory issues. They also said that the recommended daily allowance for this chemical is 0.2 milligrams, or about one 10th of one teaspoon. It is unclear what the concentration is when this chemical is paired with other substances. This substance isn’t safe since it hasn’t been thoroughly tested.
The abstract of the view demonstrates the use of diindolylmethane in cancer treatment is based on the idea that intracellular inhibition of pyruvate metabolism via flavenoids is a possibility to block and stops the accumulation of oxalates and pyruvate metabolites in renal tubule cells. The toxicology studies of the drug metabiplicate have not proven that this chemical could cause overdose. In June 1996, the Food and Drug Administration approved the drug as a prescription drug. According to the FDA the manufacturer of firestone tincture is currently in the process of completing two major clinical trials – one in Europe and one in the United States.
The abstract of the view also reveals that the use of diindolylmethane (DIEM) in the context of treating cancer is based on the principle of inhibiting intracellular inhibition of pyruvate metabolite by flavenoids, and thus blocking the accumulation of oxalates in renal tubule cells as well as Adenine granulocytes. Metabiplicate toxicology studies on the drug have not shown that this chemical is able to cause overdose. The Food and Drug Administration approved this substance as a prescribed drug in June 1996. According to the FDA the manufacturer of firestone tincture is in the process of completing two major trials–one in Europe and another in the United States. According to FDA, the FDA states that the maker of firestone Tincture is currently completing two major trials in Europe and one in the United States.